MP
Therapeutic Areas
Tyra Biosciences Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Dabogratinib (ACH) | Achondroplasia / Skeletal Dysplasia | Phase 2 |
| Dabogratinib (Onc) | Non-Muscle Invasive Bladder Cancer (NMIBC) | Phase 1/2 |
| TYRA-430 | Hepatocellular Carcinoma (HCC) & FGF19+/FGFR4+ solid tumors | Phase 1 |
| TYRA-200 | Intrahepatic Cholangiocarcinoma (ICC) & FGFR2+ solid tumors | Phase 1 |
Leadership Team at Tyra Biosciences
SO
Sherry Owens
Clinical
ES
Ed Slezinger
CLINICAL
ED
Elisa Daley
CLINICAL
MR
Marc Rideout
Research
AG
Adele Gulfo
Board Member
LA
Leslie Aguilar
Clinical
MP
Melissandre Pache
Research
CD
Curt Dvorak
Chemistry
TB
Tonya Blizzard
FINANCE
JH
Jonathan Holt
Medical Affairs